Recombinant human adenovirus p53 combined with transcatheter arterial chemoembolization for liver cancer: A meta-analysis

Yaru Guo, Yuanyuan Chen, Yingnan Zhang, Mengjun Xu, Wenwen Guo, Jingya Zhang, Gaolei Ma, Chen Liu, Juan Yang and Xiaojin Wu

PLOS ONE, 2023, vol. 18, issue 12, 1-23

Abstract: Objectives: To compare the clinical curative effects, survival and complications of recombinant human adenovirus-p53 (rAd-p53) combined with transcatheter arterial chemoembolization (TACE) versus TACE for the treatment of liver cancer. Methods: We searched all the eligible studies of rAd-p53 plus TACE versus control group had only TACE in the treatment of liver cancer, which were retrieved from CNKI, Wanfang database, CBM, VIP, PubMed, EMBase, The Chrance of Library, Web of Science from its inception to august 2022. Results: A total of 17 studies were included, which involved 1045 patients. The results of the meta analysis indicated that the the rAd-p53combined with TACE markedly improved the patients’ complete remission(OR = 2.19, 95% CI:1.13–4.22, P = 0.02), partial remission (OR = 2.22, 95% CI:1.67–2.94, P

Date: 2023
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0295323 (text/html)
https://journals.plos.org/plosone/article/file?id= ... 95323&type=printable (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:plo:pone00:0295323

DOI: 10.1371/journal.pone.0295323

Access Statistics for this article

More articles in PLOS ONE from Public Library of Science
Bibliographic data for series maintained by plosone ().